Article

Third-Line CAR T-Cell Therapy Improves Outcomes in B-Cell Lymphomas

Author(s):

CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel.

Stephen J. Schuster, MD

Stephen J. Schuster, MD

Outcomes for patients with relapsed/refractory B-cell lymphoma (BCL) have improved since the introduction of chimeric antigen receptor (CAR) T cell therapy in the third-line setting. CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network (NCCN) guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel (liso-cel; Breyanzi).1

Version 3.2021 of the B-cell lymphoma NCCN guidelines includes a recommendation for the use of axicabtagene ciloleucel (axi-cel; Yescarta), liso-cel, or tisagenlecleucel (Kymriah) after 2 or more prior chemoimmunotherapy regimens for patients with diffuse large B-cell lymphoma (DLBCL) and other BCLs, with these recommendations assigned a category 2A.

Prior to the era of CAR T cell therapy in the setting of DLBCL, “we could cure a little over half of patients with first-line rituximab [Rituxan] plus chemotherapy2 and with our second line of therapy [high-dose chemotherapy plus autologous stem cell transplant], we can add about another 14% to the surviving patients,”3 said Stephen J. Schuster, MD, in a virtual presentation during the 2021 NCCN Virtual Annual Conference.

Approximately another 11% of patients with DLBCL will survive with third-line CAR T therapy,4,5 up from 4% in the pre-CAR T era,6 assuming a failure rate of 69% for second-line stem cell transplant and approximately one-third of patients without disease progression at 5 years with the use of CD19-directed CAR T cells, said Schuster, who is director of the Lymphoma Program at the University of Pennsylvania.

In the updated NCCN guidelines, axi-cel is indicated for the treatment of adults with relapsed/refractory large BCL, including DLBCL, not otherwise indicated, primary mediastinal large BCL (PMBCL), and DLBCL arising from follicular lymphoma (FL).

Liso-cel is an option for the treatment of patients with relapsed/refractory DLBCL, PMBCL, relapsed/refractory high-grade BCLs with translocations of MYC and BCL-2 and/or BCL-6 (double-/triple-hit lymphoma), and high-grade BCLs, not otherwise specified.

Tisagenlecleucel is indicated for the treatment of adults with relapsed/refractory large BCL, including DLBCL, not otherwise specified, and DLBCL arising from follicular lymphoma. Tisagenlecleucel is not approved by the FDA, however, for the treatment of patients with relapsed/refractory PMBCL, Schuster noted.

The 3 registrational trials that prompted the approval of CD19-directed CAR T cell therapy for patients with relapsed/refractory DLBCL are ZUMA-1, JULIET, and TRANSCEND NHL001. The data from these 3 studies support CAR T-cell therapy as “the best option for patients as third-line therapy,” he said.

In ZUMA-1,7 conducted in patients with chemo-refractory BCLs, primarily those with DLBCL not otherwise specified (NOS; 76%) but also PMBCL or transformed FL (24%), treatment with axi-cel led to a median PFS of 5.9 months, with the PFS curve starting to plateau at about 6 months. “Very few events occur after 1 year,” said Schuster.

In JULIET,8 conducted primarily in patients with DLBCL, about one-third of patients treated with tisagenlecleucel were free of disease at 1 year. Patients in remission at 3 months “had about a 70% chance of long-term disease-free survival,” and those in complete remission (CR) at 12 months had approximately a 95% or better chance of long-term disease-free survival, he said. Five-year follow-up data from JULIET shows a response duration of about 60%; a similar duration of response is anticipated for axi-cel and liso-cel, he indicated.

TRANSCEND NHL0019 examined the effect of liso-cel in patients with DLBCL NOS (51% of the study cohort), transformed FL (22%), indolent non-Hodgkin lymphoma (7%), high-grade BCL (13%), and PMBCL (6%). The 1-year PFS rate was 44% of patients in the overall study cohort, which improved to 65% in those with a CR. The probability of PFS was highest in patients with PMBCL and transformed FL; the median was not yet reached in either group.

There is still an unmet need in DLBCL, as survival is about 80% with the use of third-line CAR T-cell treatment, said Schuster. Improvement in apheresis and cell manufacturing and optimal patient selection could improve outcomes further. Looking ahead, the combination of CAR T-cell therapy with immune checkpoint inhibitors and the use of CAR T-cell therapy in earlier lines, among other strategies, may offer opportunities to enhance outcomes.

References

  1. Schuster SJ. Updates on CAR T-cell therapy for relapsed/refractory B-cell lymphomas. Presented at: 2021 NCCN Virtual Annual Conference; March 18-20, 2021; virtual.
  2. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126. doi: 10.1200/JCO.2005.09.131
  3. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190. doi:10.1200/JCO.2010.28.1618
  4. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545-2554. doi:10.1056/NEJMoa1708566
  5. Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673-4. doi:10.1056/NEJMc2030164
  6. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage. Bone Marrow Transplant. 2016;51(1):51-57. doi:10.1038/bmt.2015.213
  7. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42. doi:10.1016/S1470-2045(18)30864-7
  8. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56. doi: 10.1056/NEJMoa1804980
  9. Abramson J, Lia Palomba M, Gordon LI, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet. 2020(1);396:839-852. doi:10.1016/S1470-2045(18)30864-7
Related Videos
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Alex Herrera, MD
Grzegorz S. Nowakowski, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Amitkumar Mehta, MD
Grzegorz S. Nowakowski, MD
Jasmin M. Zain, MD
Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowski, MD